Thomas Kampourakis, Diplom, PhD, was selected for funding through AHA鈥檚 competitive Pilot Grant program for his project, 鈥淯sing chemo-proteomics to identify new SGLT2 inhibitor targets in the heart.鈥 This award recognizes Dr. Kampourakis鈥檚 innovative research and its potential to improve our understanding of heart health.
Dr. Kampourakis started at the University of Kentucky about 16 months ago and launched his new lab in April 2024 after moving from King鈥檚 College London, England. He is driven by the thrill of scientific discovery 鈥 uncovering new insights and translating those findings into meaningful advancements that ultimately help patients.
At 海角禁区 HealthCare, Dr. Kampourakis values the division of cardiovascular medicine for its unique blend of basic, translational, and medical science, as well as its extremely supportive environment. This support was especially important during their transition from England, helping him adjust to the U.S. systems for grant funding and regulatory approval.
This strong foundation has empowered Dr. Kampourakis to hit the ground running, laying the groundwork for research that bridges the gap between discovery and patient care.